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ABSTRACT: The cytogenetic study of a nodal metastasis from a gastric carcinoma, after two passages 
in nude mice, revealed a Jarge number of double minutes. Comparative genomic in situ hybridization 
(CGH) analysis using DNA extracted from this xenograft revealed the existence of three ciear amplifica­
tion units that originated from the chromosomal subregions 6q24-25, 7q31-32, and 8q24 in the xenograft 
DNA. Similar, though less prominent, CGH results were found with DNAs extracted from the primary 
tumor and its metastasis, implying that the same amplicons were also present, albeit less abundantly, 
in the DNAs of these neoplastic tissues. Southern analysis of the second-passage xenograft detected 18- 
and 10-fold amplification of MET (located at 7q31) and MYC (located at 8q24), respectively. The  retrospec­
tive study of the first passage of the xenograft, as well as of the metastatic and primary tumors before 
xenografting, showed amplification levels of MET of, respectively 12-, 9 and 5-fold and MYC of respec­
tively 8 7-, and 5-fold. Our results suggest that increased levels of co-amplification of MYC and MET 
correlate with enhanced growth potential in this case of gastric carcinoma,
INTRODUCTION
The MET gene located at 7cj31 is one of the protooncogenes 
most frequently altered in stomach cancer [1], This protoon­
cogene encodes a growth factor receptor controlling cell 
proliferation of epithelial cells of the liver and of the gas­
trointestinal tract [2]. Amplification and abnormal expres­
sion of the MET gene are common events in all histologic 
types of primary gastric cancer, as well as in gastric cancer- 
derived cell lines [3, 4]. A good correlation has been observed 
between amplification of the MET gene and advanced clinical 
stages and poor prognosis of patients with gastric cancer [4].
Amplification of MYC is a frequently reported phenome­
non in human malignancies [5], supposedly conferring in 
vitro proliferative advantage to tumor cells [6, 7]. Several 
reports described amplification of MYC in gastric carcinomas 
transplanted into nude mice. However, most of these studies 
did not determine whether amplification of this oncogene
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takes place before transplantation or during passage in the 
nude mice [8-11].
In an attempt to determine the timing of amplification of 
MET and MYC in gastric cancer, we studied retrospectively 
a case of gastric carcinoma in which amplification of these 
oncogenes had been found in xenografts.
MATERIALS AND METHODS
A primary gastric carcinoma and a regional lymph node 
metastasis from a 39-year-old male were studied.
Hematoxylin-and-eosin-stained sections were used to 
classify the tumor according to Laurén [12]. The growth pat­
tern was classified according to Ming [13]. Fresh samples from 
the nodal metastasis were heterotransplanted into nude mice.
Fresh material from the xenograft (passage 2) was stud­
ied by conventional cytogenetics and fluorescence in situ hy­
bridization analysis. DNA extracted from frozen material from 
the primary tumor, lymph node metastasis, and xenografts 
(passage 1 and 2) were available for Southern and compara­
tive genomic in situ hybridization (CGH) analyses.
Tumor Heterotransplantation
Mice of the N:NIH(s)II-nu/nu strain [14] were raised from 
stocks obtained from the Animal House, Medical School, 
University of Cape Town, Cape Town , South Africa, and were 
maintained under sterile conditions throughout the experi­
ments.
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Tumor specimens from the nodal metastasis were cut in 
pieces 4 to 5 mm in diameter and transplanted subcutane- 
ously (s.c.) in the interscapular regions of male and female 
nude mice. The growth of the tumors was monitored once a 
week by ruler measurement of tumor length (a) and width (b). 
Tumor volumes were estimated by the formula: V(mm3) = 
axb2 x 1/2.
Tumor volumes were plotted versus days after implanta­
tion and tumor doubling times (Td) calculated.
Cytogenetic Analysis
For chromosome analysis, the xenografted tum or [passage 
2) was surgically resected and processed directly as previ­
ously described [15]. Part of the chromosome preparations 
was GTG-banded and part stained only with Giemsa,
Comparative Genomic In Situ Hybridization (CGH)
DNAs of the primary tumor, lymph node metastasis, and 
xenograft were isolated according to standard protocols and 
used for CGH analysis [16,17] as described elsewhere [18,19].
In short, tumor and reference (46,XY) DNAs were differen­
tially labeled with biotin-14-dATP (BRL, Gaithersburg, MD) 
and digoxigenin-ll-dUTP (Boehringer Mannheim, Germany), 
respectively, using commercially available nick translation 
systems. An amount of 150-400 ng of both DNAs was 
coprecipitated in the presence of 50-100 x Cot-l-DNA [BRL], 
dissolved in 10 |iL hybridization mixture [20], denatured, 
preannealed at 37°C for 30 minutes and, finally, used for hy­
bridization to denatured BrdU-incorporated high-resolution 
metaphase spreads obtained from a normal male. Hybrid­
ization was carried out at 37°C for 3-4 days in a moist cham­
ber. Visualization of hybridizing DNAs was accomplished 
using Texas-Red-conjugated avidin and biotinylated anti- 
avidin antibodies (both from Vector Laboratories, Burlingame, 
CA) for biotin-labeled probes and fluorescein-conjugated 
sheep anti-digoxigenin (Boehringer Mannheim, Germany) 
and fluorescein-conjugated donkey anti-sheep (Jackson Immu- 
noresearch, West Grove, PA) for digoxigenin-labeled probes. 
Slides were immersed in antifade-solution [20], supple­
mented with the blue DNA-specific dye DAPI (Sigma, St. 
Louis, MO) for (G-banded-like) counterstaining of the chro­
mosomes.
Evaluation and accurate screening of the CGH results were 
attained using a Zeiss Axiophot epifluorescence microscope 
equipped with a Photometries high-performance CH250/H 
cooled CCD-camera (Photometries, Tucson, AZ) interfaced 
onto a Macintosh Quadra 950 computer.
Image acquisition, processing, superimposement, and 
display (in red-green-blue pseudocolors) were accomplished 
using the ONCOR Image F.I.S.H. software package (ONCOR 
Imaging, Gaithersburg, MD). CGH analysis of recorded meta­
phase spreads, allowing the detection and chromosomal 
(sub)localization of genomic regions that are over- or under­
represented in the tumor DNA as revealed via an increased 
or decreased Texas Red-versus-FITC (i.e., tumor-versus-nor- 
mal) fluorescence ratio, was performed using the Compara­
tive Genomic Hybridization applications within the ONCOR 
Image F.I.S.H. software package, as described previously [18,
Figure 1 One metaphase (Giemsa-banded) from the xenograft tu ­
mor (2nd passage) showing m ultiple abnormal chromosomes and 
double minutes.
19]. Photographic recording of CGH results was carried out 
with a Tektronix Phaser II DSX color printer.
CGH standardization experiments, using normal hum an 
DNA as test and reference DNA, revealed that for every chro­
mosome the test vs. reference fluorescence profile virtually 
never deviated below 0.85 or above 1.15 (heterochromatic 
regions, like centromeres and telomeres, were excluded for 
CGH analysis [16]). For this reason we used these values as 
thresholds to determine the presence of DNA under- and over­
representation (CGH ratio lower than 0.85 and higher than 
1.15, respectively) in the tumor genome(s).
Amplification Analysis
Iiigh-molecular-weight DNA was isolated using standard 
procedures [21]. For amplification studies DNA was digested 
with the restriction enzyme EcoRI, electrophoresed on 
agarose gels, blotted onto nylon membranes, and hybridized 
with probe MYC exon 1 cDNA and MET probe (American 
Type Culture Collection, Rockville, MD). The degree of am­
plification was calculated by rehybridizing the blots with a 
control probe. COL1A2 (collagen 1 pro-2-chain), The au­
toradiograms were scanned using an automated scanning 
densitometer (LKB Gelscan XL).
RESULTS
Tumorigenicity and Growth Characteristics
The tumorigenicity rate of the neoplastic tissue retrieved from 
the metastasis was 100% (6/6). Subsequent to repeat trans­
fer, a permanent tumor line was established. Total tumor 
transplant ability for seven generations was 100%.
The time that elapsed between inoculation and the inter­
polated theoretical volume of 100 m m 3 (the delay time to 
100 mm3) varied from 46 days on passage 1 to 22 days on 
passage 2, for an implanted tumor fragment of 4 m m 3.
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Cytogenetics
We analyzed 10 metaphases from the xe no grafted tumor (pas­
sage 2). Figure 1 shows one of the metaphases showing mul­
tiple numerical and structural abnormalities, as well as mul­
tiple double minutes.
Comparative Genomic In Situ Hybridization
CGH analyses were carried out to identify and define the ori­
gin and localization of the supernumerary DNA sequences 
within the DNA of the tumor xenograft. In all 10 metaphase 
spreads examined, the hybridization patterns of tumor and 
normal DNAs depicted two easily discernible, overrepre­
sented genomic regions on chromosomes 7 (7^31-32) and 8 
(8q24), and a considerably less discernible one on chromo­
some 6 (6q24-25) (Fig. 2).
Similar results were found using DNAs of the primary tu­
mor and its metastasis as test DNA (not shown]. The level 
of overrepresentation of the three amp 1 icons in DNAs of the 
primary tumor and nodal metastasis appeared nevertheless 
lower than that observed in the xenograft DNA: lower tumor- 
versus-normal ratios for each of the three respective chro­
mosomal regions, and less easily and less frequently observed 
amplicons by CGH in the tumor and the metastasis than in 
the xenograft (not shown). These results imply that the level 
of amplification of the 6q-, 7q~, and 8q-derived genomic 
regions, in the DNAs of the primary tumor and its nodal 
metastasis, is lower than that encountered in the DNA of the 
xenograft.
Amplification Analysis
All tumor samples (primary tumor, lym ph node metastasis, 
and the tumor material recovered from each of the two pas­
sages of the heterotransplanted metastasis) showed amplifi­
cation of MET and MYC (Fig. 3). Amplification levels of MET 
were 5-, 9-, 12-, and 18-fold in, respectively, the primary tu­
mor, metastasis (before xe nografting), passage 1 of the xeno­
graft, and passage 2 of the xenograft. Amplification levels 
of MYC were of 5-, 7-, 8-, and 10-fold in, respectively, the pri­
mary tumor, metastasis (before xenografting), passage 1 of 
the xenograft, and passage 2 of the xenograft.
DISCUSSION
Gastric carcinomas are among the hum an epithelial tumors 
less frequently studied (cyto)genetically, partly at least be­
cause it is difficult to grow gastric cancer cells in vitro [11, 
22], In an attempt to overcome this limitation we have used 
nude mice as recipients for xenografts of gastric tumors, Re­
cently, a similar approach was successfully used by others 
[8-11], enabling the establishment of gastric cancer-derived 
cell lines after a number of passages in  nude mice. These 
results suggest that during heterotransplantation, (subpopu­
lations of) tumor cells acquire an intrinsic growth advantage 
or benefit from the absence of inhibitory signals from stromal 
cells present in the primary tumor.
Cytogenetically, the xenograft studied by us (passage 2) 
showed massive chromosome abnormalities and double min­
utes, a cytogenetic evidence of gene amplification [5, 23, 24].
A
B
C
F ig u re  3 Southern blot illustrating the increasing levels of MET 
(A) and MYC (B) amplification in comparison to a control probe (C). 
T, primary tumor; M, lymph node metastasis; XI, xenografted tu ­
mor (first passage); X2, xenografted tum or (second passage).
In an attempt to localize the regions where these genetic 
imbalances had occurred, CGH analysis was carried out [16, 
17], This technique provides a straightforward approach for 
detection of gains and losses of whole chromosomes or chro­
mosomal segments [18, 19, 25], even in the absence of con­
ventional cytogenetic studies [17, 26].
The CGH finding of two clearly discernible amplicons 
originating from 7q31~32 and 8q24 in the DNA of the 
xenografted tumor was in keeping w ith the possibility that 
proto-oncogenes MET and MYC, which are located in 7q31 
[27] and 8q24 [28-30], respectively, were amplified. This sug­
gestion was confirmed by Southern analysis, w hich revealed 
levels of 18-fold and 10-fold amplification of MET and MYC, 
respectively, in the same material. The discrepancy in the 
* levels of amplification for the two genomic regions as esti­
mated by CGH and molecular amplification analyses is prob­
ably due to a general technical limitation of the CGH tech­
nique [16], which consists in  the fact that the height of the 
estimated turnor-versus-normal CGH ratio does not quantita­
tively reflect the level of amplification in cases of increased 
gene copy numbers (i.e., amplicons).
Amplification and abnormal expression of MET gene has 
been reported in a number of gastric cancer-derived cell lines, 
as well as in primary gastric carcinomas [4, 31]. Preferential 
retention of a duplicated marker chromosome containing the 
amplified MET gene has been observed after endoredupli- 
cation of MNK45, a poorly differentiated gastric carcinoma 
cell line, suggesting a gene dosage effect along the several 
passages during in vitro cultures [31],
The co-amplification of the MYC oncogene observed by 
us in  the xenograft is in keeping w ith previous observations 
of frequent amplifications of this gene in gastric carcinomas 
transplanted in mice [8-11],
Retrospective amplification analysis of MET and MYC 
showed that all specimens (primary tumor, nodal metasta-
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sis, and passage 1 of the xenograft) had amplification of both 
genes, thus demonstrating that this phenomenon was already 
present in the neoplastic tissues of the patient. The increased 
levels of amplification of both genes in the xenografts as com­
pared to the primary and metastatic tum or may be caused, 
partly at least, by a greater mixture of the tumor cells and 
stromal cells in the fresh samples. Alternatively, our obser­
vations may indicate the progressive selection of cells with 
high levels of MET and MYC co-amplification. In our opin­
ion, the multistep increase of the amplification levels favors 
the latter possibility.
The higher number of copies of MET and MYC in the 
metastasis and passage 2 of the xenograft as compared to, 
respectively, the primary tum or and passage 1 in  the nude 
mice, suggests a relationship between MET and MYC am­
plification and growth rate of the neoplastic cells. This hy­
pothesis is further supported by the progressive increase of 
the percentage of S-phase cells, as assessed by DNA flow 
cytometry (data not shown), and by the observation that the 
delay time to 100 mm3 dropped from 46 days in passage 1 
to 22 days in passage 2.
Altogether, our main conclusions are: 1) in the case herein 
described, MET and MYC amplification was prior to hetér­
otransplantation; 2) the levels of amplification increased from 
primary tumor to nodal metastasis, and along several pas­
sages in nude mice; 3) the levels of amplification of MET and 
MYC appear to be related with the rate of proliferation of the 
xenografted tumor cells in the nude mice.
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